Medical/Pharmaceuticals
Drawing on Experience, United Imaging Prepares Transportable CTs for U.S. Deployment
HOUSTON, March 31, 2020 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, is preparing to deploy readily transportable CT scanners inthe United States to help in the fight against COVID-19, said a company spokesperson. United Imaging began wor...
2020-03-31 20:00
1082
Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy
SAN DIEGO, March 31, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) announced today that its drug Silmitasertib (CX-4945) was determined to be a potential treatment forCOVID-19. To date, COVID-19, has infected over 700,000 people and killed over 34,000 people worldwide. COVID-19 is a ...
2020-03-31 19:00
1373
China Pharma Holdings, Inc. Reports Fiscal Year 2019 Financial Results
HAIKOU CITY, China, March 31, 2020 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the ...
2020-03-31 18:30
9183
Fosun Pharma Announces 2019 Annual Results
SHANGHAI, March 31, 2020 /PRNewswire/ -- On March 30 2020, Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, announced its annual results for the year 2019 ("the reporting period"). During the reporting period: ...
2020-03-31 17:51
11067
3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2%
HONGKONG, March 31, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2019 annual results, showing that the Company maintained steady growth, with core products continuously leading the market and more products being included into drug reimbursemen...
2020-03-31 12:29
9442
Alphamab Oncology, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China
SUZHOU, China, March 30, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced today that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab"), a wholly-owned subsidiary of the Company, has established strategic partnership with Simcere and 3D Medicines (Beijing) Co....
2020-03-30 19:00
3376
Ascentage Pharma Releases 2019 Annual Results, Reports Increased Investment in R&D and Advances in Global Clinical Development
SUZHOU, China and ROCKVILLE, MD, March 29, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for the...
2020-03-30 08:00
1697
GenScript ProBio Congratulates XlifeSciences on the Start of TAEST16001 Early Phase Clinical Trial
NANJING, China, March 27, 2020 /PRNewswire/ -- Guangzhou XlifeSciences, a partner of GenScript ProBio (GenScript's CDMO segment) announced that the early phase clinical trial of TAEST16001 project has been started. GenScript ProBio extends congratulations on this. This clinical trial project is ...
2020-03-27 21:00
2260
Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib)
SUZHOU, China, March 27, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced today that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab"), a wholly-owned subsidiary of the Company, has entered a clinical supply agreement with Pfizer Inc. ("Pfizer") to advance a ...
2020-03-27 19:00
4257
Luye Pharma Continues to Deliver Strong Growth in 2019
SHANGHAI, March 27, 2020 /PRNewswire/ -- Luye Pharma Group (02186.HK) reported its financial results for 2019 onMarch 27, 2020. According to the results, the company has achieved a total revenue ofRMB 6.358 billion, up 22.9% year-on-year. EBITDA wasRMB 2.488 billion, up 26.9% year-on-year; and n...
2020-03-27 16:44
5611
CStone submits new drug application for the targeted therapy avapritinib in Taiwan for the treatment of adults with advanced PDGFRA exon 18 mutant gastrointestinal stromal tumor
SUZHOU, China, March 27, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for avapritinib, a precision therapy being developed for the t...
2020-03-27 14:02
1604
Fosun Pharma's Novel Coronavirus Nucleic Acid Detection Kit Receives Emergency Approval from China NMPA
SHANGHAI, March 26, 2020 /PRNewswire/ -- Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March"), a wholly-owned subsidiary ofShanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), has received emergency approval from the National Medica...
2020-03-26 22:27
7333
WuXi Biologics Achieved Remarkable Results in 2019
57.2% Revenue Growth to RMB3,983.7 Million 63.0% Gross Profit Growth to RMB1,658.8 Million Adjusted Net Profit Up 60.3% to RMB1,205.0 Million Diluted EPS of RMB0.76 and Adjusted Diluted EPS of RMB0.91, Increasing 58.3% and 59.6% Backlog Increased 40.2% to US$5.1 Billion Milestone Payments Surg...
2020-03-26 21:32
5910
Bio-Pharm Solutions Expands from Epilepsy to Neurodegenerative Diseases Aiming for IPO
SUWON, South Korea, March 26, 2020 /PRNewswire/ -- Bio-Pharm Solutions Co., Ltd. has expanded its clinical pipelines from infantile spasms (IS) to status epilepticus (SE) and Alzheimer's disease. Based on the performance of its first pipeline, an infantile spasms drug, BIo-Pharm Solutions is c...
2020-03-26 21:00
1399
Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID
SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership inEurope SEATTLE and BRISBANE, Australia, ...
2020-03-26 14:00
1504
AAHRPP Accredits Three More Research Organizations, Including First in Australia and Walter Reed National Military Medical Center
WASHINGTON, March 26, 2020 /PRNewswire/ -- The Association for the Accreditation of Human Research Protection Programs today announced that it has awarded accreditation to its first organization inAustralia, a second U.S. Department of Defense entity and one of the largest hospitals inTaiwan. Th...
2020-03-26 00:48
1699
Happiness Biotech Announced Breakthrough in Developing Covid-19 Testing Kits
NANPING, China, March 25, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that the Company, together with Fuzhou University, have achieved a breakthrough in developing Cov...
2020-03-25 20:00
4605
SonoScape Shares its Experience of Fighting Against COVID-19 to the Global Community
SHENZHEN, China, March 24, 2020 /PRNewswire/ -- SonoScape, one of the leading providers of ultrasound and endoscopy solutions, headquartered inShenzhen China , started to help with the coronavirus epidemic as early as in January. The company worked against time with top priority of ensuring the he...
2020-03-25 09:32
5062
Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted
SHENZHEN, China, March 24, 2020 /PRNewswire/ -- On March 23th, 2020, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's application for Investigational New Drug (IND) of CS12192 has been accepted by Center for Drug Evaluation, ...
2020-03-24 19:25
1654
WuXi AppTec Reports Strong 2019 Annual Results
Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 38.2% Year-Over-Year toRMB2,407 Million Adjusted Diluted Non-IFRS EPS Up by 19.7% to RMB1.46[1] SHANGHAI, March 24, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. ...
2020-03-24 18:56
6832
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 303 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8683
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5536
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5116
Yingli Solar's Global Product Workshops Launched in Malaysia
2024-11-15 21:40
4753
